An epigenetic pathway regulates MHC-II expression and function in B cell lymphoma models

Area of Science:

• Immunology
• Molecular Biology
• Epigenetics

Background:

• Mutations in MHC class II (MHC-II) genes are common in B cell lymphomas and affect patient survival.
• Mechanisms controlling MHC-II expression, including genetic and epigenetic factors, require further elucidation.

Purpose of the Study:

• To identify key signaling pathways regulating MHC-II gene expression.
• To investigate the role of BAP1, IRF1, and CIITA in MHC-II regulation.
• To explore epigenetic therapeutic strategies for B cell lymphomas.

Main Methods:

• Identified the BAP1/IRF1/CIITA signaling axis.
• Studied the impact of BAP1/IRF1/CIITA disruption on MHC-II expression and immune infiltration in B cell lymphoma models.
• Investigated the effect of pharmacological inhibition of Polycomb Repressive Complex 1 (PRC1) on MHC-II expression in BAP1-deficient cells.

Main Results:

• Disruption of the BAP1/IRF1/CIITA pathway attenuates MHC-II expression and immune cell infiltration, accelerating tumor growth.
• Pharmacological inhibition of PRC1 restores MHC-II gene expression in BAP1-deficient B cell lymphoma cells.
• BAP1 acts as a tumor suppressor by modulating the tumor microenvironment and immune response.

Conclusions:

• BAP1 plays a critical role in regulating MHC-II expression through the IRF1/CIITA pathway.
• Epigenetic targeting of PRC1 offers a potential strategy to restore MHC-II expression in B cell lymphomas.
• Restoring tumor-specific MHC-II expression may enhance immunotherapy outcomes in B cell lymphoma treatment.